MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

<p>LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-chlorine-gas-induced-lung-injury-accepted-for-presentation-at-the-63rd-annual-meeting-of-the-society-of-toxicology/">MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>